Literature DB >> 12374106

Therapeutic applications of sugar-mimicking glycosidase inhibitors.

N Asano1, A Kato, A A Watson.   

Abstract

Sugar-mimicking alkaloids inhibit the glycosidases involved in a wide range of important biological processes, principally owing to their structural resemblance to the sugar moiety of the natural substrate. The possibility of modifying and blocking these processes by using such inhibitors for therapeutic applications has attracted a lot of attention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12374106     DOI: 10.2174/1389557013407052

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  6 in total

1.  Discovery of a β-glucosidase inhibitor from a chemically engineered extract prepared through sulfonylation.

Authors:  Mario O Salazar; Oscar Micheloni; Andrea M Escalante; Ricardo L E Furlan
Journal:  Mol Divers       Date:  2011-01-06       Impact factor: 2.943

2.  Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells.

Authors:  Terry D Butters; Dominic S Alonzi; Nikolay V Kukushkin; Yuan Ren; Yves Blériot
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

3.  Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB.

Authors:  Elizabeth Ficko-Blean; Keith A Stubbs; Oksana Nemirovsky; David J Vocadlo; Alisdair B Boraston
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

4.  Enantioselective synthesis of polyhydroxyindolizidinone and quinolizidinone derivatives from a common precursor.

Authors:  Nemai Saha; Shital K Chattopadhyay
Journal:  Beilstein J Org Chem       Date:  2014-12-22       Impact factor: 2.883

5.  Antidiabetic potential of two medicinal plants used in Gabonese folk medicine.

Authors:  Huguette Agnaniet; Elvis Jolinom Mbot; Ousmane Keita; Jean-Alain Fehrentz; Anita Ankli; Audrey Gallud; Marcel Garcia; Magali Gary-Bobo; Jacques Lebibi; Thierry Cresteil; Chantal Menut
Journal:  BMC Complement Altern Med       Date:  2016-02-22       Impact factor: 3.659

6.  N α-arylsulfonyl histamines as selective β-glucosidase inhibitors.

Authors:  M O Salazar; M I Osella; I A Ramallo; R L E Furlan
Journal:  RSC Adv       Date:  2018-10-24       Impact factor: 3.361

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.